亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Novel Diabetes Treatment

总结: Researchers at Purdue University in collaboration with Oklahoma Medical Research Foundation have developed and assayed a series of lead compounds that act as memapsin 1 inhibitors and increase pancreatic beta cell mass. Treatment with these compounds may also be complimented by other therapeutics that increase insulin production, improve glucose homeostasis, or inhibit hyperglucagonemia.

*Background: Diabetes is a widely prevalent disease that currently affects 25.8 million people in the United States. The predominant form of diabetes is characterized by hyperglycemia resulting from a combination of reduction in pancreatic beta cell activity and mass, which leads to insufficient insulin production. An enzyme called memapsin 1 is known to be part of the biochemical pathway that leads to the problems with pancreatic beta cells and ultimately causes insulin deficiency. Memapsin 1 deactivates a transmembrane protein shown to increase beta cell proliferation and improve glucose stimulated insulin secretion. The transmembrane protein is deactivated when it undergoes ectodomain cleavage in a process triggered by memapsin 1.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，请点击这里